Novartis To Acquire Cooley-Led Biotech Biz For $1.4B
Novartis AG said Tuesday it has agreed to buy U.S. biotechnology company Tourmaline Bio Inc. for approximately $1.4 billion in a move to bolster the Swiss company's portfolio of cardiovascular disease...To view the full article, register now.
Already a subscriber? Click here to view full article